Introduction and marketing status of dutasteride soft capsules

Dutasteride (Dutasteride) is a 5α- reductase inhibitor, mainly used to treat benign prostatic hyperplasia (BPH) and male pattern alopecia (AGA). It works by inhibiting 5α-reductase 1 type and < type span>2, reduces the production of dihydrotestosterone (DHT), thereby reducing prostate size, improving urinary symptoms, reducing hair follicle shrinkage and promoting hair growth in hair loss treatment. Compared with another 5α- reductase inhibitor - finasteride (Finasteride), dutasteride has a more comprehensive and potent inhibitory effect on DHT.

Dutasteride was first developed by GlaxoSmithKline (GSK) and was approved for marketing by the FDA in 2001 under the trade name "Avodart". Since then, the drug has been gradually approved in many countries and regions around the world for the treatment of benign prostatic hyperplasia, and in some regions it has also been approved for the treatment of male pattern baldness. Due to the expiration of its patent protection, many pharmaceutical companies have launched generic drugs on the market, including versions produced in India, Laos and other countries.

In China, dutasteride soft capsules have been approved for marketing by the National Food and Drug Administration (NMPA) and are suitable for patients with prostatic hyperplasia. Because of its clear efficacy, it can be purchased in domestic medical institutions and pharmacies, but the price varies depending on the brand and place of origin. In recent years, with the increasing demand for men's health management, the application of dutasteride in the treatment of hair loss has also received widespread attention. Although its indication for hair loss has not been officially approved in China, it has been used by many patients clinically.

Dutasteride original drugAvodartThe price is higher, while generic drugs are relatively cheap, especially the versions produced in India, Laos and other places, the price is only a fraction of the original drug. Dutasteride has been included in the scope of medical insurance reimbursement in some areas. Patients can consult local hospitals or pharmacies for specific medical insurance reimbursement conditions when purchasing. In addition, patients should purchase through formal channels to ensure drug quality and safety.

Reference materials: http://www.nmpa.gov.cn/